---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-23-000037"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:23:12.802994+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agios Q4 2022 net income $36.5M on PYRUKYND revenue $4.3M; cash $1.1B

## Summary
- PYRUKYND net revenue $4.3M in Q4 2022, $11.7M full year; 78 patients on therapy, up 39% QoQ.
- Net income from continuing ops $36.5M in Q4 vs loss $98.6M in Q4 2021; full-year net loss $231.8M.
- Cash, equivalents and marketable securities $1.1B as of Dec 31, 2022, down from $1.3B year-end 2021.
- Completed enrollment in Phase 2 RISE UP sickle cell study; on track to complete Phase 3 thalassemia enrollment by mid-2023.
- Appointed Tsveta Milanova as chief commercial officer; received EU and Great Britain approvals for PYRUKYND.

## SEC filing metadata
- accession: 0001439222-23-000037
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/0001439222-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/agio-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-23-000037
- JSON: https://secwatch.observer/filing/0001439222-23-000037.json
- Plain text: https://secwatch.observer/filing/0001439222-23-000037.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue Net U.S. product revenue from sales of PYRUKYND® was $4.3 million for the fourth quarter of 2022, and $11.7 million for, net income Net income was $36.5 million for the fourth quarter of 2022 compared to a net loss of $98.6 million for the fourth quart.
  - Period: the fourth quarter and year ended Dec. 31, 2022
  - Revenue: Net U.S. product revenue from sales of PYRUKYND® was $4.3 million for the fourth quarter of 2022, and $11.7 million for
  - Net income: Net income was $36.5 million for the fourth quarter of 2022 compared to a net loss of $98.6 million for the fourth quart
  - Result: reported results
  source text: Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended Dec. 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000037/0001439222-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.